Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma

Cancer Science

Volumn 99, Issue 5, 2008, Pages 958-966

  Imai, Takashi ^a   Toyota, Minoru ^a   Suzuki, Hiromu ^a   Akino, Kimishige ^a   Ogi, Kazuhiro ^a   Sogabe, Yohei ^a   Kashima, Lisa ^a   Maruyama, Reo ^a   Nojima, Masanori ^a   Mita, Hiroaki ^a   Sasaki, Yasushi ^a   Itoh, Fumio ^b   Imai, Kohzoh ^a   Shinomura, Yasuhisa ^a   Hiratsuka, Hiroyoshi ^a   Tokino, Takashi ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 2; RAS PROTEIN; PROTEIN; RASSF2 PROTEIN, HUMAN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL GROWTH; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE DELETION; GENE MUTATION; GENETIC SCREENING; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; METASTASIS; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SQUAMOUS CELL CARCINOMA; GENETIC EPIGENESIS; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUTH TUMOR; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; IMMUNOHISTOCHEMISTRY; MOUTH NEOPLASMS; PROTEINS;

EID: 43649098854     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00769.x     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Gangane N, Chawla S, Subodh A, Gupta S, Sharma SM. Reassessment of risk factors for oral cancer. Asian Pac J Cancer Prev 2007; 8: 243-8.
3. Petti S, Scully C. Oral cancer: The association between nation-based alcohol-drinking profiles and oral cancer mortality. Oral Oncol 2005; 41: 828-34.
4. Chiba I, Shindoh M, Yasuda M et al. Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity. Oncogene 1996; 12: 1663-8.
5. Ha PK, Califano JA. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 2006; 7: 77-82.
6. Ogi K, Toyota M, Ohe-Toyota M et al. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 2002; 8: 3164-71.
7. Ushijima T, Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from? Cancer Sci 2005; 96: 206-11.
8. Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res 2007; 13: 1634-7.
9. Nakayama S, Sasaki A, Mese H et al. The E-cadherin gene is silenced by CpG methylation in human oral squamous cell carcinomas. Int J Cancer 2001; 93: 667-73.
10. Ogi K, Toyota M, Mita H et al. Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors. Cancer Biol Ther 2005; 4: 773-80.
11. Shaw RJ, Liloglou T, Rogers SN et al. Promoter methylation of P16, RARβ, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer 2006; 94: 561-8.
12. Tran TN, Liu Y, Takagi M, Yamaguchi A, Fujii H. Frequent promoter hypermethylation of RASSF1A and p16INK4a and infrequent allelic loss other than 9p21 in betel-associated oral carcinoma in a Vietnamese non-smoking/non-drinking female population. J Oral Pathol Med 2005; 34: 150-6.
13. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.
14. Kuo MY, Jeng JH, Chiang CP, Hahn LJ. Mutations of K-ras oncogene codon 12 in betel quid chewing-related human oral squamous cell carcinoma in Taiwan. J Oral Pathol Med 1994; 23: 70-4.
15. Munirajan AK, Mohanprasad BK, Shanmugam G, Tsuchida N. Detection of a rare point mutation at codon 59 and relatively high incidence of H-ras mutation in Indian oral cancer. Int J Oncol 1998; 13: 971-4.
16. Sakai E, Rikimaru K, Ueda M et al. The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. Int J Cancer 1992; 52: 867-72.
17. Dammann R, Li C, Yoon JH et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21. 3 Nat Genet 2000; 25: 315-19.
18. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001; 61: 3105-9.
19. Akino K, Toyota M, Suzuki H et al. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 2005; 129: 156-69.
20. Endoh M, Tamura G, Honda T et al. RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Cancer 2005; 93: 1395-9.
21. Hesson LB, Wilson R, Morton D et al. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 2005; 24: 3987-94.
22. Kaira K, Sunaga N, Tomizawa Y et al. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers. Int J Oncol 2007; 31: 169-73.
23. Zhang Z, Van Sun D, Do N et al. Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer 2007; 120: 32-8.
24. Ueno M, Toyota M, Akino K et al. Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol 2004; 25: 134-40.
25. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucl Acids Res 1994; 22: 2990-7.
26. Elewaut D, DiDonato JA, Kim JM et al. NF-κB is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria. J Immunol 1999; 163: 1457-66.
27. Kimura YN, Watari K, Fotovati A et al. Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci 2007; 98: 2009-18.
28. Yamanaka N, Morisaki T, Nakashima H et al. Interleukin 1β enhances invasive ability of gastric carcinoma through nuclear factor-κB activation. Clin Cancer Res 2004; 10: 1853-9.
29. Cox AD, Der CJ. The dark side of Ras: Regulation of apoptosis. Oncogene 2003; 22: 8999-9006.
30. Sparmann A, Bar-Sagi D. Ras oncogene and inflammation: Partners in crime. Cell Cycle 2005; 4: 735-6.
31. Hocker M, Rosenberg I, Xavier R et al. Oxidative stress activates the human histidine decarboxylase promoter in AGS gastric cancer cells. J Biol Chem 1998; 273: 23.046-54.
32. Reimers N, Kasper HU, Weissenborn SJ et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007; 120: 1731-8.
33. Sakamoto-Hojo ET, Mello SS, Pereira E et al. Gene expression profiles in human cells, submitted to genotoxic stress. Mutat Res 2003; 544: 403-13.
34. Kiziltepe T, Hideshima T, Catley L et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 2007; 6: 1718-27.
35. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540-50.
36. Katayama A, Bandoh N, Kishibe K et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 2004; 10: 634-40.
37. Abiko Y, Nishimura M, Kusano K et al. Expression of MIP-3α/CCL20, a macrophage inflammatory protein in oral squamous cell carcinoma. Arch Oral Biol 2003; 48: 171-5.
38. Romashkova JA, Makarov SS. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401: 86-90.
39. Andela VB, Schwarz EM, Puzas JE, O'Keefe RJ, Rosier RN. Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor κB. Cancer Res 2000; 60: 6557-62.
40. Bobrovnikova-Marjon EV, Marjon PL, Barbash O, Vander Jagt DL, Abcouwer SF. Expression of angiogenic factors, vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: Role of nuclear factor-κB and activating protein-1. Cancer Res 2004; 64: 4858-69.
41. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004; 6: 447-58.
42. Allen NP, Donninger H, Vos MD et al. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 2007; 26: 6203-11.